Information on Providing Care during the COVID-19 pandemic

Published March 6, 2020.  Last updated March 25, 2020  1:45PM This section originally contained information on providing virtual care for your patients.  Given the rapidly changing situation with COVID-19 we have expanded to […]

Read More…


ORA Supports the OMA Policy on Distancing and Statement on Use of Hydroxychloroquine for COVID-19

The ORA offers its support of the new revised OMA policy on Physical Distancing.  In particular we support the revised guidance for “Physical Distancing and Social Isolation” which makes even more explicit the […]

Read More…


EAP Renewals Automatically Extended for 90 Days

Good news! We have heard from David Schachow, Director, Drug Programs Delivery Branch, that the Ontario Public Drug Programs is authorizing the automatic extension of all EAP approvals with a funding date that […]

Read More…


Special Message from the ORA President regarding COVID-19

Published March 16, 2020.  12:50PM Dear Members, March break is usually a time of family, travel, relaxation and welcoming signs of Spring. Instead of that, this year we are faced with an entirely […]

Read More…


ORA Position Statement on Infusion Clinics

The ORA has created a position statement on infusion clinics during the COVID-19 pandemic.  The position update may be updated over the coming weeks so please check back often. Link: ORA position on […]

Read More…


Important Announcement about the 2020 Annual Scientific Meeting

Managing concerns around COVID-19: An updated message to our community about the ORA Annual Scientific Meeting taking place April 17-19, 2020 at the Kingbridge Conference Centre Published March 12, 2020.   Last updated March […]

Read More…


Disappointing News – Official Cancellation of 2020 ORA Annual Scientific Meeting

Managing concerns around COVID-19: An updated message to our community about the ORA Annual Scientific Meeting taking place April 17-19, 2020 at the Kingbridge Conference Centre Published March 12, 2020.   Last updated March […]

Read More…


ORA & MOHLTC Partnership

The ORA has enjoyed a longstanding partnership with the MOHLTC that is beneficial to everyone in the arthritis community. Recently David Schachow, Director, Drug Programs Delivery wrote a letter to the ORA to […]

Read More…


Biosimilar Transitioning – Guidelines and Educational Resources

Here are some educational resources on biosimilar transitioning that the ORA endorses: Arthritis Consumer Experts (ACE) has produced a special biosimilars education video series, where ACE speaks to medical experts on key patient […]

Read More…


ORA Biosimilar Position Statement

The ORA published a position statement on administrative switching in 2015 and updated it again in the Fall of 2018. The full position statement is available using the link below: ORA Position on […]

Read More…